# A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

> **NCT04478279** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sapience Therapeutics** · enrollment: 125 (actual)

## Conditions studied

- Glioblastoma
- Melanoma Stage IV
- Breast Cancer
- Prostate Cancer
- Glioblastoma Multiforme
- GBM
- Brain Cancer
- Metastatic Breast Cancer
- Metastatic Melanoma
- Metastatic Prostate Cancer
- Melanoma Recurrent
- Prostate Cancer Metastatic
- Recurrent Glioblastoma
- Newly Diagnosed Glioblastoma

## Interventions

- **DRUG:** ST101
- **DRUG:** Temozolomide
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT04478279
- **Lead sponsor:** Sapience Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-01
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04478279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04478279, "A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT04478279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*